Screener / SEC EDGAR /CIK 0000019584 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Home Health Care Services

Chemed Corp CHE

Compare with peers Embed
Earnings releases

Latest results release: Oct 27, 2026

8-K item 2.02, exhibit 99

What CHE's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

In its release of Oct 27, 2026, CHE reported $5.45 per share under GAAP and $6.75 on its own adjusted basis: the adjusted number is +24% above GAAP.

GAAP EPS $5.90, release Feb 27, 2024: 31, 2023 Consolidated operating results: · Revenue increased 7.2% to $585.9 million · GAAP Diluted Earnings-per-Share (EPS) of $5.90, an increase of 42.9% · Adjusted Dilute Adjusted EPS $6.60, release Feb 27, 2024: Revenue increased 7.2% to $585.9 million · GAAP Diluted Earnings-per-Share (EPS) of $5.90, an increase of 42.9% · Adjusted Diluted EPS of $6.60, an increase of 35.0% VITAS segment ope +12% 2024-02 GAAP EPS $4.24, release Apr 24, 2024: 31, 2024 Consolidated operating results: · Revenue increased 5.2% to $589.2 million · GAAP Diluted Earnings-per-Share (EPS) of $4.24, an increase of 18.4% · Adjusted Dilute Adjusted EPS $5.20, release Apr 24, 2024: Revenue increased 5.2% to $589.2 million · GAAP Diluted Earnings-per-Share (EPS) of $4.24, an increase of 18.4% · Adjusted Diluted EPS of $5.20, an increase of 21.5% VITAS segment ope +23% 2024-04 GAAP EPS $4.65, release Jul 24, 2024: 30, 2024 Consolidated operating results: · Revenue increased 7.6% to $595.9 million · GAAP Diluted Earnings-per-Share (EPS) of $4.65, an increase of 32.5% · Adjusted Dilute Adjusted EPS $5.47, release Jul 24, 2024: Revenue increased 7.6% to $595.9 million · GAAP Diluted Earnings-per-Share (EPS) of $4.65, an increase of 32.5% · Adjusted Diluted EPS of $5.47, an increase of 34.1% VITAS segment ope +18% 2024-07 GAAP EPS $5.00, release Oct 29, 2024: 30, 2024 Consolidated operating results: · Revenue increased 7.4% to $606.2 million · GAAP Diluted Earnings-per-Share (EPS) of $5.00, an increase of 1.4% · Adjusted Diluted Adjusted EPS $5.64, release Oct 29, 2024: · Revenue increased 7.4% to $606.2 million · GAAP Diluted Earnings-per-Share (EPS) of $5.00, an increase of 1.4% · Adjusted Diluted EPS of $5.64, an increase of 6.0% VITAS segment oper +13% 2024-10 GAAP EPS $6.02, release Feb 26, 2025: 31, 2024 Consolidated operating results: · Revenue increased 9.2% to $640.0 million · GAAP Diluted Earnings-per-Share (EPS) of $6.02, an increase of 2.0% · Adjusted Diluted Adjusted EPS $6.83, release Feb 26, 2025: · Revenue increased 9.2% to $640.0 million · GAAP Diluted Earnings-per-Share (EPS) of $6.02, an increase of 2.0% · Adjusted Diluted EPS of $6.83, an increase of 3.5% VITAS segment oper +14% 2025-02 GAAP EPS $4.86, release Apr 23, 2025: 31, 2025 Consolidated operating results: · Revenue increased 9.8% to $646.9 million · GAAP Diluted Earnings-per-Share (EPS) of $4.86, an increase of 14.6% · Adjusted Dilute Adjusted EPS $5.63, release Apr 23, 2025: Revenue increased 9.8% to $646.9 million · GAAP Diluted Earnings-per-Share (EPS) of $4.86, an increase of 14.6% · Adjusted Diluted EPS of $5.63, an increase of 8.3% VITAS segment oper +16% 2025-04 GAAP EPS $3.57, release Jul 29, 2025: 30, 2025 Consolidated operating results: · Revenue increased 3.8% to $618.8 million · GAAP Diluted Earnings-per-Share (EPS) of $3.57, a decrease of 23.2% · Adjusted Diluted Adjusted EPS $4.27, release Jul 29, 2025: · Revenue increased 3.8% to $618.8 million · GAAP Diluted Earnings-per-Share (EPS) of $3.57, a decrease of 23.2% · Adjusted Diluted EPS of $4.27, a decrease of 21.9% VITAS segment oper +20% 2025-07 GAAP EPS $4.46, release Oct 28, 2025: 30, 2025 Consolidated operating results: · Revenue increased 3.1% to $624.9 million · GAAP Diluted Earnings-per-Share (EPS) of $4.46, a decrease of 10.8% · Adjusted Diluted Adjusted EPS $5.27, release Oct 28, 2025: · Revenue increased 3.1% to $624.9 million · GAAP Diluted Earnings-per-Share (EPS) of $4.46, a decrease of 10.8% · Adjusted Diluted EPS of $5.27, a decrease of 6.6% VITAS segment opera +18% 2025-10 GAAP EPS $5.48, release Feb 25, 2026: results: · Revenue was $639.3 million, essentially flat with the fourth quarter of 2024 · GAAP Diluted Earnings-per-Share (EPS) of $5.48, a decrease of 9.0% · Adjusted Diluted Adjusted EPS $6.42, release Feb 25, 2026: flat with the fourth quarter of 2024 · GAAP Diluted Earnings-per-Share (EPS) of $5.48, a decrease of 9.0% · Adjusted Diluted EPS of $6.42, a decrease of 6.0% VITAS segment opera +17% 2026-02 GAAP EPS $4.84, release Apr 23, 2026: 31, 2026 Consolidated operating results: · Revenue increased 1.6% to $657.5 million · GAAP Diluted Earnings-per-Share (EPS) of $4.84, a decrease of 0.4% · Adjusted Diluted Adjusted EPS $5.65, release Apr 23, 2026: · Revenue increased 1.6% to $657.5 million · GAAP Diluted Earnings-per-Share (EPS) of $4.84, a decrease of 0.4% · Adjusted Diluted EPS of $5.65, an increase of 0.4% VITAS segment oper +17% 2026-04 GAAP EPS $5.13, release Jul 28, 2026: 30, 2026 Consolidated operating results: · Revenue increased 8.8% to $673.3 million · GAAP Diluted Earnings-per-Share (EPS) of $5.13, an increase of 43.7% · Adjusted Dilute Adjusted EPS $6.06, release Jul 28, 2026: Revenue increased 8.8% to $673.3 million · GAAP Diluted Earnings-per-Share (EPS) of $5.13, an increase of 43.7% · Adjusted Diluted EPS of $6.06, an increase of 41.9% VITAS segment ope +18% 2026-07 GAAP EPS $5.45, release Oct 27, 2026: 30, 2026 Consolidated operating results: · Revenue increased 10.6% to $690.9 million · GAAP Diluted Earnings-per-Share (EPS) of $5.45, an increase of 22.2% · Adjusted Dilute Adjusted EPS $6.75, release Oct 27, 2026: Revenue increased 10.6% to $690.9 million · GAAP Diluted Earnings-per-Share (EPS) of $5.45, an increase of 22.2% · Adjusted Diluted EPS of $6.75, an increase of 28.1% VITAS segment ope +24% 2026-10
GAAP EPSAdjusted EPS, as the company defines itThe figure on top is how far adjusted is from GAAP. Click a bar for the sentence.
The company's words, latest release
30, 2026 Consolidated operating results: · Revenue increased 10.6% to $690.9 million · GAAP Diluted Earnings-per-Share (EPS) of $5.45, an increase of 22.2% · Adjusted Dilute release
Revenue increased 10.6% to $690.9 million · GAAP Diluted Earnings-per-Share (EPS) of $5.45, an increase of 22.2% · Adjusted Diluted EPS of $6.75, an increase of 28.1% VITAS segment ope release

What the company says its adjusted numbers leave out:

This press release contains information about Chemed’s EBITDA, Adjusted EBITDA, and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude components that are important to understanding Chemed’s financial performance. release Oct 27, 2026

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Oct 27, 2026 · EX-99

CONTACT: Michael D. Witzeman (513) 762- 6714 Chemed Reports Third-Quarter 2026

Open on SEC

CONTACT: Michael D. Witzeman (513) 762- 6714 Chemed Reports Third-Quarter 2026 Results CINCINNATI, October 27, 2026— Chemed Corporation (Chemed) (NYSE: CHE ), which operates VITAS Healthcare Corporation (VITAS), the nation’s largest providers of end-of-life care, and Roto-Rooter , the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its third quarter ended September 30, 2026, versus the comparable prior-year period. Results for Quarter Ended September 30, 2026 Consolidated operating results:

· Net Income, excluding certain discrete items, of $70.8 million, an increase of 44.7%

· Adjusted EBITDA, excluding Medicare Cap, of $92.5 million, an increase of 31.4%

· Adjusted EBITDA margin, excluding Medicare Cap, of 20.2%, an increase of 318-basis points

· Net Income, excluding certain discrete items, of $33.3 million, a decline of 1.8%

VITAS VITAS net revenue was $457.4 million in the third quarter of 2026, which is an increase of 12.2% when compared to the prior-year period. This revenue increase is comprised primarily of a 9.4% increase in days-of-care and a geographically weighted average Medicare reimbursement rate increase of approximately 2.2%. Acuity mix shift negatively impacted revenue growth 25-basis points in the quarter when compared to the prior-year period’s revenue and level-of-care mix. The combination of Medicare Cap and other contra revenue changes positively impacted revenue growth by 85-basis points. Total VITAS admissions increased 7.2% in the third quarter of 2026 compared to the third quarter of 2025. In the third quarter of 2026, VITAS accrued $828,000 in Medicare Cap billing limitation. This compares to the Medicare Cap billing limitation recorded in the third quarter of 2025 of $6.1 million. No Medicare Cap billing limitation was recorded in the third quarter of 2026 for the Florida combined program, and none is anticipated for the 2026 fiscal period. Of VITAS’ 33 Medicare provider numbers, 21 provider numbers have an anticipated full-year Medicare Cap cushion of 10% or greater, seven provider numbers have a cushion between 0% and 10%, and five provider numbers have a Medicare Cap billing limitation totaling $6.1 million. Average revenue per patient per day in the third quarter of 2026 was $209.11 which is 196-basis points above the prior-year period. Reimbursement for routine home care and high-acuity care averaged $187.69 and $1,147.26, respectively. During the quarter, high-acuity days-of- care were 2.2% of total days of care, a decline of 5-basis points when compared to the prior-year quarter. The third quarter 2026 gross margin, excluding Medicare Cap, was 25.4%, a 221-basis point increase from the same period of 2025. Selling, general and administrative expenses were $23.1 million in the third quarter of 2026 compared to $25.2 million in the prior-year quarter. Adjusted EBITDA, excluding Medicare Cap, totaled $92.5 million in the quarter, an increase of 31.4% when compared to the prior-year period. Adjusted EBITDA margin in the quarter, excluding Medicare Cap, was 20.2%. Roto-Rooter Roto- Rooter generated quarterly revenue of $233.5 million in the third quarter of 2026, an increase of 7.5%, when compared to the prior-year quarter. Roto-Rooter branch commercial revenue in the quarter totaled $59.9 million, an increase of 9.0% from the prior-year period. This aggregate commercial revenue change consisted of plumbing increasing 10.6%, drain cleaning increasing 6.8%, excavation increasing 5.5% and water restoration increasing 30.7%. Roto-Rooter branch residential revenue in the quarter totaled $158.8 million, an increase of 5.2% over the prior-year period. This aggregate residential revenue change consisted of excavation increasing 7.8%, plumbing increasing 5.9%, water restoration increasing 6.2% and drain cleaning increasing 4.5%. In the third quarter of 2026, revenue from independent contractors was $16.9 million which is flat compared to the same period of 2025. Roto-Rooter’s third quarter 2026 gross margin was 50.3%. This compares to the prior-year quarter’s gross margin of 50.7%. Roto-Rooter’s selling, general and administrative expenses were $71.0 million in the quarter, which is an increase of 17.1% compared to the third quarter of 2025. Adjusted EBITDA in the third quarter of 2026 totaled $48.2 million, a decline of 2.5% when compared to the third quarter of 2025. Adjusted EBITDA margin in the quarter was 20.6% which represents a 213-basis point decline from the third quarter of 2025. During the third quarter of 2026, Roto- Rooter re-acquired multiple franchise territories in California for approximately $62.5 million. Collectively, these territories include a population of over 12 million people. Slightly over half of the revenue associated with acquired territories will become part of our owned and operated branch locations. Two new branches will be established in Sacramento and San Diego while other territories will be absorbed by existing branches. The remaining locations will become part of our independent contractor operating model. Chemed Consolidated As of September 30, 2026, Chemed had total cash and cash equivalents of $48.4 million and $236.0 million in long-term debt. In April 2026, Chemed entered into a new five-year $450 million Amended and Restated Credit Agreement (Credit Agreement). This Credit Agreement consists of a $450 million revolving line of credit and a $250 million expansion feature. The interest rate on this Credit Agreement has a floating rate that is currently SOFR plus 100-basis points. There is approximately $166.7 million undrawn borrowing capacity under the Credit Agreement after excluding $47.3 million for Letters of Credit. During the quarter, the Company repurchased 125,000 shares of Chemed stock for $66.0 million which equates to a cost per share of $528.24. Over the trailing 12-months, the Company has repurchased 1,235,000 shares of Chemed stock at an average price of $427.62 per share. As of September 30, 2026, there was approximately $73.7 million of remaining share repurchase authorization under the Company’s plan. Guidance Update Based on the Company’s financial results through September 30, 2026, we estimate that we will be at or slightly above the high-end of our full-year 2026 adjusted EPS guidance issued in conjunction with our press release, dated July 28, 2026, discussing our second quarter 2026 earnings. Further operational detail will be provided during the investor conference call. Conference Call As previously disclosed, Chemed will host a conference call and webcast at 10 a.m. ET, on Wednesday October 28, 2026, to discuss the company's quarterly results and to provide an update on its business. Participants may access a live webcast of the conference call through the investor relations section of Chemed’s website, Investor Relations Home | Chemed Corporation or the hosting website https://edge.media- server.com/mmc/p/v5gcs68f . Participants may also register via teleconference at: https://register-conf.media- server.com/register/BId8ccb8a390cc4b6fbb29ab2b99a55028 . Once registration is completed, participants will be provided with a dial-in number containing a personalized conference code to access the call. All participants are instructed to dial-in 15 minutes prior to the start time. A taped replay of the conference call will be available beginning approximately two hours after the call's conclusion. You may access the replay via webcast through the investor relations section of Chemed’s website. Chemed operates in the healthcare field through its VITAS Healthcare Corporation subsidiary. VITAS provides daily hospice services to patients with severe, life-limiting illnesses. This type of care is focused on making the terminally ill patient's final days as comfortable and pain-free as possible. Chemed operates in the residential and commercial plumbing and drain cleaning industry under the brand name Roto-Rooter. Roto-Rooter provides plumbing, drain cleaning, and water cleanup services through company-owned branches, independent contractors and franchisees in the United States and Canada. Roto-Rooter also has licensed master franchisees in the republics of Indonesia and Singapore, and the Philippines.

This press release contains information about Chemed’s EBITDA, Adjusted EBITDA, and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude components that are important to understanding Chemed’s financial performance. In reporting its operating results, Chemed provides EBITDA, Adjusted EBITDA and Adjusted Diluted EPS measures to help investors and others evaluate the Company’s operating results, compare its operating performance with that of similar companies that have different capital structures and evaluate its ability to meet its future debt service, capital expenditures and working capital requirements. Chemed’s management similarly uses EBITDA, Adjusted EBITDA, and Adjusted Diluted EPS to assist it in evaluating the performance of the Company across fiscal periods and in assessing how its performance compares to its peer companies. These measures also help Chemed’s management to estimate the resources required to meet Chemed’s future financial obligations and expenditures. Chemed’s EBITDA, Adjusted EBITDA and Adjusted Diluted EPS should not be considered in isolation or as a substitute for comparable measures calculated and presented in accordance with GAAP. We calculated Adjusted EBITDA margin by dividing Adjusted EBITDA by service revenue and sales. A reconciliation of Chemed’s Net Income to its EBITDA, Adjusted EBITDA and Adjusted Diluted EPS is presented in the tables following the text of this press release. SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 REGARDING FORWARD-LOOKING INFORMATION Statements in this press release contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods and are based upon assumptions subject to certain known and unknown risks, uncertainties, contingencies and other factors, including, but not limited to, the impact of laws and regulations on Chemed’s operations, including Medicare Cap and Medicare reimbursement rates, Chemed’s estimates of the effect of Medicare Cap on VITAS’ revenues and future prospects, Chemed’s expectations regarding VITAS’ patient mix and Chemed’s expectations regarding demand for Roto-Rooter’s services. Because forward- looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Chemed’s control. Chemed’s actual results and financial condition may differ materially from those indicated in the forward- looking statements included in this press release, including as a result of the risks described above and those described in Chemed’s Annual Report on Form 10-K for the year ended December 31, 2025 and in its Quarterly Reports filed in 2026. Any forward-looking statement made by Chemed in this press release is based only on information currently available to Chemed and speaks only as of the date on which it is made. Chemed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

 CHEMED CORPORATION AND SUBSIDIARY COMPANIES CONSOLIDATED BALANCE SHEETS (in thousands, except per share data)(unaudited)    Assets September 30, Current assets 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash equivalents $ 48,427 $ 129,752 Accounts receivable less 254,861 215,570 allowances Inventories 7,748 8,238 Prepaid income taxes 16,346 7,106 Prepaid expenses 38,346 34,577 Total current assets 365,728 395,243 Investments of deferred compensation 144,845 136,021 plans held in trust Properties and equipment, at cost less 216,961 203,939 accumulated depreciation Lease right of use asset 144,029 128,362 Identifiable intangible assets less 78,791 84,930 accumulated amortization Goodwill 754,758 666,987 Other assets 13,327 8,137 Total Assets $ 1,718,439 $ 1,623,619 Liabilities Current liabilities Accounts payable $ 65,297 $ 48,095 Accrued insurance 77,044 65,733 Accrued income taxes - 1,469 Accrued compensation 89,044 79,668 Short-term lease liability 41,209 42,013 Other current liabilities 58,340 55,063 Total current liabilities 330,934 292,041 Deferred income taxes 18,855 9,687 Deferred compensation 142,421 132,380 liabilities Long-term debt 236,000 - Long-term lease liability 114,985 99,461 Other liabilities 13,823 13,367 Total Liabilities 857,018 546,936 Stockholders' Equity Capital stock 37,762 37,593 Paid-in capital 1,693,508 1,581,067 Retained earnings 3,135,794 2,887,123 Treasury stock, at cost -4,008,128 -3,431,475 Deferred compensation payable in Company 2,485 2,375 stock Total Stockholders' Equity 861,421 1,076,683 Total Liabilities and Stockholders' $ 1,718,439 $ 1,623,619 Equity

 CHEMED CORPORATION AND SUBSIDIARY COMPANIES CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands)(unaudited)    For the Nine Months Cash Flows from Ended September 30, Operating Activities 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 205,653 $ 188,487 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 51,260 48,511 amortization Stock option expense 24,285 24,374 Noncash long-term 6,784 3,057 incentive compensation Legal settlements 6,000 1,850 Noncash directors' 1,191 1,123 compensation Benefit for deferred -456 -16,259 income taxes Amortization of debt 255 241 issuance costs Changes in operating assets and liabilities, excluding amounts acquired in business combinations: Increase in accounts -71,304 -44,403 receivable Increase in -205 -45 inventories Increase in prepaid -11,528 -8,603 expenses Increase in accounts payable and other current 27,783 10,102 liabilities Change in current -7,685 -2,162 income taxes Net change in lease assets and -667 -576 liabilities (Increase)/decrease in -9,356 42,048 other assets Increase in other 6,772 6,355 liabilities Other sources 840 639 Net cash provided by operating 229,622 254,739 activities Cash Flows from Investing Activities Business combinations, net of cash -96,050 -225 acquired Capital expenditures -51,355 -46,447 Proceeds from sale of 488 3,751 fixed assets Other uses -502 -468 Net cash used by -147,419 -43,389 investing activities Cash Flows from Financing Activities Proceeds from revolving line of 843,280 - credit Payments on revolving -607,280 - line of credit Purchases of treasury -350,042 -256,944 stock Proceeds from exercise 30,281 27,152 of stock options Dividends paid -25,234 -23,196 Change in cash 6,818 610 overdrafts payable Capital stock surrendered to pay taxes -3,832 -8,484 on stock-based compensation Debt issuance costs -1,349 - Other (uses)/sources -933 914 Net cash used by -108,291 -259,948 financing activities Decrease in Cash and -26,088 -48,598 Cash Equivalents Cash and cash equivalents at 74,515 178,350 beginning of year Cash and cash equivalents at end of $ 48,427 $ 129,752 period

VITAS has 14 large (greater than 450 ADC), 25 medium (greater than 200 but less than 450 ADC) and 21 small (less than 200 ADC) hospice (c) programs. Of Vitas' 33 Medicare provider numbers, for the current cap year, 21 provider numbers have a Medicare cap cushion of greater than 10%, seven provider numbers have a Medicare cap cushion between 0% and 10%, and five provider numbers have a Medicare cap liability.

Full text with the tables
CONTACT: Michael D. Witzeman (513) 762- 6714 Chemed Reports Third-Quarter 2026
Results CINCINNATI, October 27, 2026— Chemed Corporation (Chemed) (NYSE: CHE ),
which operates VITAS Healthcare Corporation (VITAS), the nation’s largest
providers of end-of-life care, and Roto-Rooter , the nation’s largest commercial
and residential plumbing and drain cleaning services provider, reported
financial results for its third quarter ended September 30, 2026, versus the
comparable prior-year period. Results for Quarter Ended September 30, 2026
Consolidated operating results:
                                                  
  ·    Revenue increased 10.6% to $690.9 million  
                                                  
                                                                             
  ·    GAAP Diluted Earnings-per-Share (EPS) of $5.45, an increase of 22.2%  
                                                                             
                                                            
  ·    Adjusted Diluted EPS of $6.75, an increase of 28.1%  
                                                            
VITAS segment operating results:
                                                                    
  ·    Net Patient Revenue of $457.4 million, an increase of 12.2%  
                                                                    
                                                                  
  ·    Average Daily Census (ADC) of 24,428, an increase of 9.4%  
                                                                  
                                                  
  ·    Admissions of 18,995, an increase of 7.2%  
                                                  
                                                                                
  ·    Net Income, excluding certain discrete items, of $70.8 million, an       
       increase of 44.7%                                                        
                                                                                
                                                                                
  ·    Adjusted EBITDA, excluding Medicare Cap, of $92.5 million, an increase   
       of 31.4%                                                                 
                                                                                
                                                                                
  ·    Adjusted EBITDA margin, excluding Medicare Cap, of 20.2%, an increase    
       of 318-basis points                                                      
                                                                                
Roto-Rooter segment operating results:
                                                       
  ·    Revenue of $233.5 million, an increase of 7.5%  
                                                       
                                                                                
  ·    Net Income, excluding certain discrete items, of $33.3 million, a        
       decline of 1.8%                                                          
                                                                                
                                                            
  ·    Adjusted EBITDA of $48.2 million, a decline of 2.5%  
                                                            
                                                                       
  ·    Adjusted EBITDA margin of 20.6%, a decline of 213-basis points  
                                                                       
VITAS VITAS net revenue was $457.4 million in the third quarter of 2026, which
is an increase of 12.2% when compared to the prior-year period. This revenue
increase is comprised primarily of a 9.4% increase in days-of-care and a
geographically weighted average Medicare reimbursement rate increase of
approximately 2.2%. Acuity mix shift negatively impacted revenue growth 25-basis
points in the quarter when compared to the prior-year period’s revenue and
level-of-care mix. The combination of Medicare Cap and other contra revenue
changes positively impacted revenue growth by 85-basis points. Total VITAS
admissions increased 7.2% in the third quarter of 2026 compared to the third
quarter of 2025. In the third quarter of 2026, VITAS accrued $828,000 in
Medicare Cap billing limitation. This compares to the Medicare Cap billing
limitation recorded in the third quarter of 2025 of $6.1 million. No Medicare
Cap billing limitation was recorded in the third quarter of 2026 for the Florida
combined program, and none is anticipated for the 2026 fiscal period. Of VITAS’
33 Medicare provider numbers, 21 provider numbers have an anticipated full-year
Medicare Cap cushion of 10% or greater, seven provider numbers have a cushion
between 0% and 10%, and five provider numbers have a Medicare Cap billing
limitation totaling $6.1 million. Average revenue per patient per day in the
third quarter of 2026 was $209.11 which is 196-basis points above the prior-year
period. Reimbursement for routine home care and high-acuity care averaged
$187.69 and $1,147.26, respectively. During the quarter, high-acuity days-of-
care were 2.2% of total days of care, a decline of 5-basis points when compared
to the prior-year quarter. The third quarter 2026 gross margin, excluding
Medicare Cap, was 25.4%, a 221-basis point increase from the same period of
2025. Selling, general and administrative expenses were $23.1 million in the
third quarter of 2026 compared to $25.2 million in the prior-year quarter.
Adjusted EBITDA, excluding Medicare Cap, totaled $92.5 million in the quarter,
an increase of 31.4% when compared to the prior-year period. Adjusted EBITDA
margin in the quarter, excluding Medicare Cap, was 20.2%. Roto-Rooter Roto-
Rooter generated quarterly revenue of $233.5 million in the third quarter of
2026, an increase of 7.5%, when compared to the prior-year quarter. Roto-Rooter
branch commercial revenue in the quarter totaled $59.9 million, an increase of
9.0% from the prior-year period. This aggregate commercial revenue change
consisted of plumbing increasing 10.6%, drain cleaning increasing 6.8%,
excavation increasing 5.5% and water restoration increasing 30.7%. Roto-Rooter
branch residential revenue in the quarter totaled $158.8 million, an increase of
5.2% over the prior-year period. This aggregate residential revenue change
consisted of excavation increasing 7.8%, plumbing increasing 5.9%, water
restoration increasing 6.2% and drain cleaning increasing 4.5%. In the third
quarter of 2026, revenue from independent contractors was $16.9 million which is
flat compared to the same period of 2025. Roto-Rooter’s third quarter 2026 gross
margin was 50.3%. This compares to the prior-year quarter’s gross margin of
50.7%. Roto-Rooter’s selling, general and administrative expenses were $71.0
million in the quarter, which is an increase of 17.1% compared to the third
quarter of 2025. Adjusted EBITDA in the third quarter of 2026 totaled $48.2
million, a decline of 2.5% when compared to the third quarter of 2025. Adjusted
EBITDA margin in the quarter was 20.6% which represents a 213-basis point
decline from the third quarter of 2025. During the third quarter of 2026, Roto-
Rooter re-acquired multiple franchise territories in California for
approximately $62.5 million. Collectively, these territories include a
population of over 12 million people. Slightly over half of the revenue
associated with acquired territories will become part of our owned and operated
branch locations. Two new branches will be established in Sacramento and San
Diego while other territories will be absorbed by existing branches. The
remaining locations will become part of our independent contractor operating
model. Chemed Consolidated As of September 30, 2026, Chemed had total cash and
cash equivalents of $48.4 million and $236.0 million in long-term debt. In April
2026, Chemed entered into a new five-year $450 million Amended and Restated
Credit Agreement (Credit Agreement). This Credit Agreement consists of a $450
million revolving line of credit and a $250 million expansion feature. The
interest rate on this Credit Agreement has a floating rate that is currently
SOFR plus 100-basis points. There is approximately $166.7 million undrawn
borrowing capacity under the Credit Agreement after excluding $47.3 million for
Letters of Credit. During the quarter, the Company repurchased 125,000 shares of
Chemed stock for $66.0 million which equates to a cost per share of $528.24.
Over the trailing 12-months, the Company has repurchased 1,235,000 shares of
Chemed stock at an average price of $427.62 per share. As of September 30, 2026,
there was approximately $73.7 million of remaining share repurchase
authorization under the Company’s plan. Guidance Update Based on the Company’s
financial results through September 30, 2026, we estimate that we will be at or
slightly above the high-end of our full-year 2026 adjusted EPS guidance issued
in conjunction with our press release, dated July 28, 2026, discussing our
second quarter 2026 earnings. Further operational detail will be provided during
the investor conference call. Conference Call As previously disclosed, Chemed
will host a conference call and webcast at 10 a.m. ET, on Wednesday October 28,
2026, to discuss the company's quarterly results and to provide an update on its
business. Participants may access a live webcast of the conference call through
the investor relations section of Chemed’s website, Investor Relations Home |
Chemed Corporation or the hosting website https://edge.media-
server.com/mmc/p/v5gcs68f . Participants may also register via teleconference
at: https://register-conf.media-
server.com/register/BId8ccb8a390cc4b6fbb29ab2b99a55028 . Once registration is
completed, participants will be provided with a dial-in number containing a
personalized conference code to access the call. All participants are instructed
to dial-in 15 minutes prior to the start time. A taped replay of the conference
call will be available beginning approximately two hours after the call's
conclusion. You may access the replay via webcast through the investor relations
section of Chemed’s website. Chemed operates in the healthcare field through its
VITAS Healthcare Corporation subsidiary. VITAS provides daily hospice services
to patients with severe, life-limiting illnesses. This type of care is focused
on making the terminally ill patient's final days as comfortable and pain-free
as possible. Chemed operates in the residential and commercial plumbing and
drain cleaning industry under the brand name Roto-Rooter. Roto-Rooter provides
plumbing, drain cleaning, and water cleanup services through company-owned
branches, independent contractors and franchisees in the United States and
Canada. Roto-Rooter also has licensed master franchisees in the republics of
Indonesia and Singapore, and the Philippines.

This press release contains information about Chemed’s EBITDA, Adjusted EBITDA,
and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP
and which exclude components that are important to understanding Chemed’s
financial performance. In reporting its operating results, Chemed provides
EBITDA, Adjusted EBITDA and Adjusted Diluted EPS measures to help investors and
others evaluate the Company’s operating results, compare its operating
performance with that of similar companies that have different capital
structures and evaluate its ability to meet its future debt service, capital
expenditures and working capital requirements. Chemed’s management similarly
uses EBITDA, Adjusted EBITDA, and Adjusted Diluted EPS to assist it in
evaluating the performance of the Company across fiscal periods and in assessing
how its performance compares to its peer companies. These measures also help
Chemed’s management to estimate the resources required to meet Chemed’s future
financial obligations and expenditures. Chemed’s EBITDA, Adjusted EBITDA and
Adjusted Diluted EPS should not be considered in isolation or as a substitute
for comparable measures calculated and presented in accordance with GAAP. We
calculated Adjusted EBITDA margin by dividing Adjusted EBITDA by service revenue
and sales. A reconciliation of Chemed’s Net Income to its EBITDA, Adjusted
EBITDA and Adjusted Diluted EPS is presented in the tables following the text of
this press release. SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES
LITIGATION REFORM ACT OF 1995 REGARDING FORWARD-LOOKING INFORMATION Statements
in this press release contain forward-looking statements within the meaning of
the safe harbor provisions of the U.S. Private Securities Litigation Reform Act
of 1995. Forward-looking statements can be identified by words such as
“anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,”
“estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will”
and similar references to future periods and are based upon assumptions subject
to certain known and unknown risks, uncertainties, contingencies and other
factors, including, but not limited to, the impact of laws and regulations on
Chemed’s operations, including Medicare Cap and Medicare reimbursement rates,
Chemed’s estimates of the effect of Medicare Cap on VITAS’ revenues and future
prospects, Chemed’s expectations regarding VITAS’ patient mix and Chemed’s
expectations regarding demand for Roto-Rooter’s services. Because forward-
looking statements relate to the future, they are subject to inherent
uncertainties, risks and changes in circumstances that are difficult to predict
and many of which are outside of Chemed’s control. Chemed’s actual results and
financial condition may differ materially from those indicated in the forward-
looking statements included in this press release, including as a result of the
risks described above and those described in Chemed’s Annual Report on Form 10-K
for the year ended December 31, 2025 and in its Quarterly Reports filed in 2026.
Any forward-looking statement made by Chemed in this press release is based only
on information currently available to Chemed and speaks only as of the date on
which it is made. Chemed undertakes no obligation to publicly update any
forward-looking statement, whether written or oral, that may be made from time
to time, whether as a result of new information, future developments or
otherwise.
                                                                                
                                                                                
  CHEM…                                                                         
  CORP…                                                                         
  AND                                                                           
  SUBS…                                                                         
  COMP…                                                                         
  CONS…                                                                         
  STAT…                                                                         
  OF                                                                            
  INCO…                                                                         
  (in                                                                           
  thou…                                                                         
  exce…                                                                         
  per                                                                           
  share                                                                         
  data…                                                                         
                                                                                
                                                                                
                                                                                
  Serv…                                                                         
  reve…                                                                         
  and                                                                           
  sales                                                                         
  Cost                                                                          
  of                                                                            
  serv…                                                                         
  prov…                                                                         
  and                                                                           
  goods                                                                         
  sold                                                                          
  Sell…                                                                         
  gene…                                                                         
  and                                                                           
  admi…                                                                         
  expe…                                                                         
  (aa)                                                                          
  Depr…                                                                         
  Amor…                                                                         
  Other                                                                         
  oper…                                                                         
  expe…                                                                         
  Total                                                                         
  costs                                                                         
  and                                                                           
  expe…                                                                         
  Inco…                                                                         
  from                                                                          
  oper…                                                                         
  Inte…                                                                         
  expe…                                                                         
  Other                                                                         
  inco…            690,940          624,9…             2,021…          1,890,…  
  (bb)             457,978          425,1…             1,351…          1,289,…  
  Inco…            111,469          105,7…             340,9…          311,685  
  befo…             14,427          13,664             42,997           40,798  
  inco…              2,974           2,570              8,263            7,713  
  taxes              7,670           2,998              7,740            3,075  
  Inco…            594,518          550,1…             1,751…          1,653,…  
  taxes     Three   96,422          74,750       Nine  270,2…          237,592  
  Net      Months  (2,097)           (457)     Months  (4,39…          (1,229)  
  inco…     Ended    2,383           9,251      Ended  11,071           13,970  
  Earn…    Septe…   96,708          83,544    Septem…  276,8…          250,333  
  Per         30,  (25,06…          (19,3…        30,  (71,2…          (61,84…  
  Share      2026   71,648    2025  64,237       2026  205,6…    2025  188,487  
 ────────────────────────────────────────────────────────────────────────────── 
  Net           $     5.49       $    4.46          $   15.46       $    12.97  
  inco…                                                                         
  Aver…                                                                         
  numb…                                                                         
  of                13,058          14,394             13,300           14,535  
  shar…                                                                         
  outs…                                                                         
  Dilu…                                                                         
  Earn…                                                                         
  Per                                                                           
  Share                                                                         
  Net           $     5.45       $    4.46          $   15.43       $    12.89  
  inco…                                                                         
  Aver…                                                                         
  numb…                                                                         
  of                13,135          14,409             13,329           14,620  
  shar…                                                                         
  outs…                                                                         
                                                                                
  (aa)                                                                          
  Sell…                                                                         
  gene…                                                                         
  and                                                                           
  admi…                                                                         
  ("SG…                                                                         
  expe…                                                                         
  comp…                                                                         
  (in                                                                           
  thou…                                                                         
                                                                                
                                                                                
            Three                                Nine                           
           Months                              Months                           
            Ended                               Ended                           
           Septe…                             Septem…                           
              30,                                 30,                           
             2026             2025               2026            2025           
  SG&A                                                                          
  expe…                                                                         
  befo…                                                                         
  long…                                                                         
  ince…                                                                         
  comp…                                                                         
  and                                                                           
  the                                                                           
  impa…                                                                         
  of                                                                            
  mark…                                                                         
  value                                                                         
  adju…                                                                         
  rela…                                                                         
  to                                                                            
  defe…                                                                         
  comp…         $  106,241       $  99,288          $  324,4…       $  301,600  
  plans                                                                         
  Mark…                                                                         
  value                                                                         
  adju…                                                                         
  rela…                                                                         
  to                                                                            
  defe…                                                                         
  comp…              2,077           6,703              9,661            6,791  
  trus…                                                                         
  Long…                                                                         
  ince…              3,151            -216              6,904            3,294  
  comp…                                                                         
  Total                                                                         
  SG&A          $  111,469       $  105,7…          $  340,9…       $  311,685  
  expe…                                                                         
                                                                                
  (bb)                                                                          
  Other                                                                         
  inco…                                                                         
  comp…                                                                         
  (in                                                                           
  thou…                                                                         
            Three                                Nine                           
           Months                              Months                           
            Ended                               Ended                           
           Septe…                             Septem…                           
              30,                                 30,                           
             2026             2025               2026            2025           
                                                                                
  Mark…                                                                         
  value                                                                         
  adju…                                                                         
  rela…                                                                         
  to                                                                            
  defe…                                                                         
  comp…         $    2,077       $   6,703          $   9,661       $    6,791  
  trus…                                                                         
  Inte…                295           2,555              1,399            7,186  
  inco…                                                                         
  Other                 11              -7                 11               -7  
  Total                                                                         
  other         $    2,383       $   9,251          $  11,071       $   13,970  
  inco…                                                                         
                                                                                
                                                                                
                                                                                
  CHEMED CORPORATION AND                                                        
  SUBSIDIARY COMPANIES                                                          
  CONSOLIDATED BALANCE SHEETS                                                   
  (in thousands, except per                                                     
  share data)(unaudited)                                                        
                                                                                
                                                                                
                                                                                
  Assets                         September 30,                                  
  Current assets                 2026                         2025              
 ────────────────────────────────────────────────────────────────────────────── 
  Cash and cash equivalents      $                  48,427    $        129,752  
  Accounts receivable less                         254,861             215,570  
  allowances                                                                    
  Inventories                                        7,748               8,238  
  Prepaid income taxes                              16,346               7,106  
  Prepaid expenses                                  38,346              34,577  
  Total current assets                             365,728             395,243  
  Investments of deferred                                                       
  compensation                                     144,845             136,021  
  plans held in trust                                                           
  Properties and equipment,                                                     
  at cost less                                     216,961             203,939  
  accumulated depreciation                                                      
  Lease right of use asset                         144,029             128,362  
  Identifiable intangible                                                       
  assets less                                       78,791              84,930  
  accumulated amortization                                                      
  Goodwill                                         754,758             666,987  
  Other assets                                      13,327               8,137  
  Total Assets                   $               1,718,439    $      1,623,619  
  Liabilities                                                                   
  Current liabilities                                                           
  Accounts payable               $                  65,297    $         48,095  
  Accrued insurance                                 77,044              65,733  
  Accrued income taxes                                   -               1,469  
  Accrued compensation                              89,044              79,668  
  Short-term lease liability                        41,209              42,013  
  Other current liabilities                         58,340              55,063  
  Total current liabilities                        330,934             292,041  
  Deferred income taxes                             18,855               9,687  
  Deferred compensation                            142,421             132,380  
  liabilities                                                                   
  Long-term debt                                   236,000                   -  
  Long-term lease liability                        114,985              99,461  
  Other liabilities                                 13,823              13,367  
  Total Liabilities                                857,018             546,936  
  Stockholders' Equity                                                          
  Capital stock                                     37,762              37,593  
  Paid-in capital                                1,693,508           1,581,067  
  Retained earnings                              3,135,794           2,887,123  
  Treasury stock, at cost                       -4,008,128          -3,431,475  
  Deferred compensation                                                         
  payable in Company                                 2,485               2,375  
  stock                                                                         
  Total Stockholders' Equity                       861,421           1,076,683  
  Total Liabilities and                                                         
  Stockholders'                  $               1,718,439    $      1,623,619  
  Equity                                                                        
                                                                                
                                                                                
                                                                                
  CHEMED CORPORATION AND                                                        
  SUBSIDIARY COMPANIES                                                          
  CONSOLIDATED                                                                  
  STATEMENTS OF CASH                                                            
  FLOWS                                                                         
  (in                                                                           
  thousands)(unaudited)                                                         
                                                                                
                                                                                
                            For the Nine Months                                 
  Cash Flows from           Ended September 30,                                 
  Operating Activities      2026                                2025            
 ────────────────────────────────────────────────────────────────────────────── 
  Net income                $                        205,653    $      188,487  
  Adjustments to                                                                
  reconcile net income                                                          
  to                                                                            
  net cash provided                                                             
  by operating                                                                  
  activities:                                                                   
  Depreciation and                                    51,260            48,511  
  amortization                                                                  
  Stock option expense                                24,285            24,374  
  Noncash long-term                                    6,784             3,057  
  incentive compensation                                                        
  Legal settlements                                    6,000             1,850  
  Noncash directors'                                   1,191             1,123  
  compensation                                                                  
  Benefit for deferred                                  -456           -16,259  
  income taxes                                                                  
  Amortization of debt                                   255               241  
  issuance costs                                                                
  Changes in operating                                                          
  assets and                                                                    
  liabilities, excluding                                                        
  amounts acquired in                                                           
  business                                                                      
  combinations:                                                                 
  Increase in accounts                               -71,304           -44,403  
  receivable                                                                    
  Increase in                                           -205               -45  
  inventories                                                                   
  Increase in prepaid                                -11,528            -8,603  
  expenses                                                                      
  Increase in accounts                                                          
  payable and                                                                   
  other current                                       27,783            10,102  
  liabilities                                                                   
  Change in current                                   -7,685            -2,162  
  income taxes                                                                  
  Net change in lease                                                           
  assets and                                            -667              -576  
  liabilities                                                                   
  (Increase)/decrease in                              -9,356            42,048  
  other assets                                                                  
  Increase in other                                    6,772             6,355  
  liabilities                                                                   
  Other sources                                          840               639  
  Net cash provided by                                                          
  operating                                          229,622           254,739  
  activities                                                                    
  Cash Flows from                                                               
  Investing Activities                                                          
  Business combinations,                                                        
  net of cash                                        -96,050              -225  
  acquired                                                                      
  Capital expenditures                               -51,355           -46,447  
  Proceeds from sale of                                  488             3,751  
  fixed assets                                                                  
  Other uses                                            -502              -468  
  Net cash used by                                  -147,419           -43,389  
  investing activities                                                          
  Cash Flows from                                                               
  Financing Activities                                                          
  Proceeds from                                                                 
  revolving line of                                  843,280                 -  
  credit                                                                        
  Payments on revolving                             -607,280                 -  
  line of credit                                                                
  Purchases of treasury                             -350,042          -256,944  
  stock                                                                         
  Proceeds from exercise                              30,281            27,152  
  of stock options                                                              
  Dividends paid                                     -25,234           -23,196  
  Change in cash                                       6,818               610  
  overdrafts payable                                                            
  Capital stock                                                                 
  surrendered to pay                                                            
  taxes                                               -3,832            -8,484  
  on stock-based                                                                
  compensation                                                                  
  Debt issuance costs                                 -1,349                 -  
  Other (uses)/sources                                  -933               914  
  Net cash used by                                  -108,291          -259,948  
  financing activities                                                          
  Decrease in Cash and                               -26,088           -48,598  
  Cash Equivalents                                                              
  Cash and cash                                                                 
  equivalents at                                      74,515           178,350  
  beginning                                                                     
  of year                                                                       
  Cash and cash                                                                 
  equivalents at end of     $                         48,427    $      129,752  
  period                                                                        
                                                                                
                                                                                
                                                                                
  CHEM…                                                                         
  CORP…                                                                         
  AND                                                                           
  SUBS…                                                                         
  COMP…                                                                         
  CONS…                                                                         
  STAT…                                                                         
  OF                                                                            
  INCO…                                                                         
  FOR                                                                           
  THE                                                                           
  THREE                                                                         
  MONT…                                                                         
  ENDED                                                                         
  SEPT…                                                                         
  30,                                                                           
  2026                                                                          
  AND                                                                           
  2025                                                                          
  (in                                                                           
  thou…                                                                         
                                                                                
                                                                                
  2026                                                          Chemed          
  (a)      VITAS            Roto-…            Corpo…            Conso…          
 ────────────────────────────────────────────────────────────────────────────── 
  Serv…                                                                         
  reve…    $      457,4…    $       233,5…    $            -    $       690,9…  
  and                                                                           
  sales                                                                         
  Cost                                                                          
  of                                                                            
  serv…                                                                         
  prov…           341,9…            115,9…                 -            457,9…  
  and                                                                           
  goods                                                                         
  sold                                                                          
  Sell…                                                                         
  gene…                                                                         
  and             23,100            71,033            17,336            111,4…  
  admi…                                                                         
  expe…                                                                         
  Depr…            5,791             8,624                12            14,427  
  Amor…               25             2,949                 -             2,974  
  Other                                                                         
  oper…            7,352                88               230             7,670  
  expe…                                                                         
  Total                                                                         
  costs           378,2…            198,6…            17,578            594,5…  
  and                                                                           
  expe…                                                                         
  Inco…                                                                         
  from            79,142            34,858            -17,5…            96,422  
  oper…                                                                         
  Inte…              -54              -145            -1,898            -2,097  
  expe…                                                                         
  Inte…                                                                         
  inte…            6,766             4,574            -11,3…                 -  
  inco…                                                                         
  Other              124                 5             2,254             2,383  
  inco…                                                                         
  Inco…                                                                         
  befo…           85,978            39,292            -28,5…            96,708  
  inco…                                                                         
  taxes                                                                         
  Inco…           -20,2…            -9,152             4,362            -25,0…  
  taxes                                                                         
  Net      $      65,708    $       30,140    $       -24,2…    $       71,648  
  inco…                                                                         
                                                                                
  2025                                                                          
  (b)                                                                           
  Serv…                                                                         
  reve…    $      407,7…    $       217,1…    $            -    $       624,9…  
  and                                                                           
  sales                                                                         
  Cost                                                                          
  of                                                                            
  serv…                                                                         
  prov…           318,0…            107,1…                 -            425,1…  
  and                                                                           
  goods                                                                         
  sold                                                                          
  Sell…                                                                         
  gene…                                                                         
  and             25,236            60,672            19,867            105,7…  
  admi…                                                                         
  expe…                                                                         
  Depr…            5,354             8,298                12            13,664  
  Amor…               26             2,544                 -             2,570  
  Other                                                                         
  oper…            3,036               -38                 -             2,998  
  expe…                                                                         
  Total                                                                         
  costs           351,6…            178,6…            19,879            550,1…  
  and                                                                           
  expe…                                                                         
  Inco…                                                                         
  from            56,074            38,555            -19,8…            74,750  
  oper…                                                                         
  Inte…              -56              -132              -269              -457  
  expe…                                                                         
  Inte…                                                                         
  inte…            5,685             4,030            -9,715                 -  
  inco…                                                                         
  Other               61                25             9,165             9,251  
  inco…                                                                         
  Inco…                                                                         
  befo…           61,764            42,478            -20,6…            83,544  
  inco…                                                                         
  taxes                                                                         
  Inco…           -14,9…            -10,4…             6,093            -19,3…  
  taxes                                                                         
  Net      $      46,771    $       32,071    $       -14,6…    $       64,237  
  inco…                                                                         
                                                                                
                                                                                
  The                                                                           
  "Foo…                                                                         
  to                                                                            
  Fina…                                                                         
  Stat…                                                                         
  are                                                                           
  inte…                                                                         
  parts                                                                         
  of                                                                            
  this                                                                          
  fina…                                                                         
  info…                                                                         
                                                                                
    
    
    
                                                                                
                                                                                
  CHEM…                                                                         
  CORP…                                                                         
  AND                                                                           
  SUBS…                                                                         
  COMP…                                                                         
  CONS…                                                                         
  STAT…                                                                         
  OF                                                                            
  INCO…                                                                         
  FOR                                                                           
  THE                                                                           
  NINE                                                                          
  MONT…                                                                         
  ENDED                                                                         
  SEPT…                                                                         
  30,                                                                           
  2026                                                                          
  AND                                                                           
  2025                                                                          
  (in                                                                           
  thou…                                                                         
                                                                                
                                                                                
                                                                                
  2026                                                          Chemed          
  (a)      VITAS            Roto-…            Corpo…            Conso…          
 ────────────────────────────────────────────────────────────────────────────── 
  Serv…                                                                         
  reve…    $      1,320…    $       700,9…    $            -    $       2,021…  
  and                                                                           
  sales                                                                         
  Cost                                                                          
  of                                                                            
  serv…                                                                         
  prov…           1,005…            346,3…                 -            1,351…  
  and                                                                           
  goods                                                                         
  sold                                                                          
  Sell…                                                                         
  gene…                                                                         
  and             75,314            206,3…            59,344            340,9…  
  admi…                                                                         
  expe…                                                                         
  Depr…           17,484            25,477                36            42,997  
  Amor…               78             8,185                 -             8,263  
  Other                                                                         
  oper…            7,432                78               230             7,740  
  expe…                                                                         
  Total                                                                         
  costs           1,105…            586,4…            59,610            1,751…  
  and                                                                           
  expe…                                                                         
  Inco…                                                                         
  from            215,3…            114,5…            -59,6…            270,2…  
  oper…                                                                         
  Inte…             -158              -466            -3,774            -4,398  
  expe…                                                                         
  Inte…                                                                         
  inte…           19,484            13,661            -33,1…                 -  
  inco…                                                                         
  Other              285                31            10,755            11,071  
  inco…                                                                         
  Inco…                                                                         
  befo…           234,9…            127,7…            -85,7…            276,8…  
  inco…                                                                         
  taxes                                                                         
  Inco…           -56,0…            -29,8…            14,763            -71,2…  
  taxes                                                                         
  Net      $      178,8…    $       97,837    $       -71,0…    $       205,6…  
  inco…                                                                         
                                                                                
  2025                                                                          
  (b)                                                                           
  Serv…                                                                         
  reve…    $      1,211…    $       679,3…    $            -    $       1,890…  
  and                                                                           
  sales                                                                         
  Cost                                                                          
  of                                                                            
  serv…                                                                         
  prov…           951,4…            338,3…                 -            1,289…  
  and                                                                           
  goods                                                                         
  sold                                                                          
  Sell…                                                                         
  gene…                                                                         
  and             76,861            183,8…            50,968            311,6…  
  admi…                                                                         
  expe…                                                                         
  Depr…           15,863            24,899                36            40,798  
  Amor…               78             7,635                 -             7,713  
  Other                                                                         
  oper…            3,155               -80                 -             3,075  
  expe…                                                                         
  Total                                                                         
  costs           1,047…            554,6…            51,004            1,653…  
  and                                                                           
  expe…                                                                         
  Inco…                                                                         
  from            163,9…            124,6…            -51,0…            237,5…  
  oper…                                                                         
  Inte…             -150              -394              -685            -1,229  
  expe…                                                                         
  Inte…                                                                         
  inte…           16,436            11,930            -28,3…                 -  
  inco…                                                                         
  Other              170                58            13,742            13,970  
  inco…                                                                         
  Inco…                                                                         
  befo…           180,3…            136,2…            -66,3…            250,3…  
  inco…                                                                         
  taxes                                                                         
  Inco…           -45,3…            -32,3…            15,851            -61,8…  
  taxes                                                                         
  Net      $      135,0…    $       103,9…    $       -50,4…    $       188,4…  
  inco…                                                                         
                                                                                
                                                                                
  The                                                                           
  "Foo…                                                                         
  to                                                                            
  Fina…                                                                         
  Stat…                                                                         
  are                                                                           
  inte…                                                                         
  parts                                                                         
  of                                                                            
  this                                                                          
  fina…                                                                         
  info…                                                                         
                                                                                
                                                                                
                                                                                
  CHEM…                                                                         
  CORP…                                                                         
  AND                                                                           
  SUBS…                                                                         
  COMP…                                                                         
  CONS…                                                                         
  SUMM…                                                                         
  OF                                                                            
  EBIT…                                                                         
  FOR                                                                           
  THREE                                                                         
  MONT…                                                                         
  ENDED                                                                         
  SEPT…                                                                         
  30,                                                                           
  2026                                                                          
  AND                                                                           
  2025                                                                          
  (in                                                                           
  thou…                                                                         
                                                                Chemed          
           VITAS            Roto-…            Corpo…            Conso…          
  2026                                                                          
  Net      $      65,708    $       30,140    $       -24,2…    $       71,648  
  inco…                                                                         
  Add/…                                                                         
  Inte…               54               145             1,898             2,097  
  expe…                                                                         
  Inco…           20,270             9,152            -4,362            25,060  
  taxes                                                                         
  Depr…            5,791             8,624                12            14,427  
  Amor…               25             2,949                 -             2,974  
  EBIT…           91,848            51,010            -26,6…            116,2…  
  Add/…                                                                         
  Inte…                                                                         
  inte…           -6,766            -4,574            11,340                 -  
  expe…                                                                         
  Inte…             -113                -5              -177              -295  
  inco…                                                                         
  Legal            6,705                 -               308             7,013  
  sett…                                                                         
  Stock                                                                         
  opti…                -                 -             5,984             5,984  
  expe…                                                                         
  Long…                                                                         
  ince…                -                 -             3,151             3,151  
  comp…                                                                         
  Acqu…                -             1,726                 -             1,726  
  expe…                                                                         
  Adju…    $      91,674    $       48,157    $       -6,046    $       133,7…  
  EBIT…                                                                         
                                                                                
  2025                                                                          
  Net      $      46,771    $       32,071    $       -14,6…    $       64,237  
  inco…                                                                         
  Add/…                                                                         
  Inte…               56               132               269               457  
  expe…                                                                         
  Inco…           14,993            10,407            -6,093            19,307  
  taxes                                                                         
  Depr…            5,354             8,298                12            13,664  
  Amor…               26             2,544                 -             2,570  
  EBIT…           67,200            53,452            -20,4…            100,2…  
  Add/…                                                                         
  Inte…                                                                         
  inte…           -5,685            -4,030             9,715                 -  
  expe…                                                                         
  Inte…              -69               -25            -2,462            -2,556  
  inco…                                                                         
  Stock                                                                         
  opti…                -                 -             6,067             6,067  
  expe…                                                                         
  Legal            2,850                 -                 -             2,850  
  sett…                                                                         
  Long…                                                                         
  ince…                -                 -              -216              -216  
  comp…                                                                         
  Other                -                 -             2,665             2,665  
  Adju…    $      64,296    $       49,397    $       -4,648    $       109,0…  
  EBIT…                                                                         
                                                                                
  The                                                                           
  "Foo…                                                                         
  to                                                                            
  Fina…                                                                         
  Stat…                                                                         
  are                                                                           
  inte…                                                                         
  parts                                                                         
  of                                                                            
  this                                                                          
  fina…                                                                         
  info…                                                                         
                                                                                
                                                                                
                                                                                
  CHEM…                                                                         
  CORP…                                                                         
  AND                                                                           
  SUBS…                                                                         
  COMP…                                                                         
  CONS…                                                                         
  SUMM…                                                                         
  OF                                                                            
  EBIT…                                                                         
  FOR                                                                           
  THE                                                                           
  NINE                                                                          
  MONT…                                                                         
  ENDED                                                                         
  SEPT…                                                                         
  30,                                                                           
  2026                                                                          
  AND                                                                           
  2025                                                                          
  (in                                                                           
  thou…                                                                         
                                                                Chemed          
           VITAS            Roto-…            Corpo…            Conso…          
  2026                                                                          
  Net      $      178,8…    $       97,837    $       -71,0…    $       205,6…  
  inco…                                                                         
  Add/…                                                                         
  Inte…              158               466             3,774             4,398  
  expe…                                                                         
  Inco…           56,088            29,899            -14,7…            71,224  
  taxes                                                                         
  Depr…           17,484            25,477                36            42,997  
  Amor…               78             8,185                 -             8,263  
  EBIT…           252,6…            161,8…            -81,9…            332,5…  
  Add/…                                                                         
  Inte…                                                                         
  inte…           -19,4…            -13,6…            33,145                 -  
  expe…                                                                         
  Inte…             -274               -31            -1,094            -1,399  
  inco…                                                                         
  Stock                                                                         
  opti…                -                 -            24,285            24,285  
  expe…                                                                         
  Legal            7,253                 -               308             7,561  
  sett…                                                                         
  Long…                                                                         
  ince…                -                 -             6,904             6,904  
  comp…                                                                         
  Acqu…                8             1,953                 -             1,961  
  expe…                                                                         
  Adju…    $      240,1…    $       150,1…    $       -18,4…    $       371,8…  
  EBIT…                                                                         
  2025                                                                          
  Net      $      135,0…    $       103,9…    $       -50,4…    $       188,4…  
  inco…                                                                         
  Add/…                                                                         
  Inte…              150               394               685             1,229  
  expe…                                                                         
  Inco…           45,353            32,344            -15,8…            61,846  
  taxes                                                                         
  Depr…           15,863            24,899                36            40,798  
  Amor…               78             7,635                 -             7,713  
  EBIT…           196,4…            169,2…            -65,5…            300,0…  
  Add/…                                                                         
  Inte…                                                                         
  inte…           -16,4…            -11,9…            28,366                 -  
  expe…                                                                         
  Inte…             -176               -58            -6,952            -7,186  
  inco…                                                                         
  Stock                                                                         
  opti…                -                 -            24,374            24,374  
  expe…                                                                         
  Long…                                                                         
  ince…                -                 -             3,294             3,294  
  comp…                                                                         
  Legal            2,850                 -                 -             2,850  
  sett…                                                                         
  Other                -                 -             2,665             2,665  
  Adju…    $      182,7…    $       157,2…    $       -13,8…    $       326,0…  
  EBIT…                                                                         
                                                                                
  The                                                                           
  "Foo…                                                                         
  to                                                                            
  Fina…                                                                         
  Stat…                                                                         
  are                                                                           
  inte…                                                                         
  parts                                                                         
  of                                                                            
  this                                                                          
  fina…                                                                         
  info…                                                                         
                                                                                
                                                                                
                                                                                
  CHEM…                                                                         
  CORP…                                                                         
  AND                                                                           
  SUBS…                                                                         
  COMP…                                                                         
  RECO…                                                                         
  OF                                                                            
  ADJU…                                                                         
  NET                                                                           
  INCO…                                                                         
  (in                                                                           
  thou…                                                                         
  exce…                                                                         
  per                                                                           
  share                                                                         
  data…                                                                         
                                                                                
                                                                                
                                                                                
                                                                                
                                                                                
  Net                                                                           
  inco…                                                                         
  as                                                                            
  repo…                                                                         
  Add/…                                                                         
  pre-…                                                                         
  cost                                                                          
  of:                                                                           
  Stock                                                                         
  opti…                                                                         
  expe…                                                                         
  Legal                                                                         
  sett…                                                                         
  Amor…                                                                         
  of                                                                            
  reac…                                                                         
  fran…                                                                         
  righ…                                                                         
  Long…                                                                         
  ince…                                                                         
  comp…                                                                         
  Acqu…                                                                         
  expe…                                                                         
  Other                                                                         
  Add/…                                                                         
  tax                                                                           
  impa…                                                                         
  Tax                                                                           
  impa…                                                                         
  of                                                                            
  the                                                                           
  above                                                                         
  pre-…                                                                         
  adju…                                                                         
  (1)                                                                           
  Exce…                                                                         
  tax                                                                           
  expe…                                                                         
  on                                                                            
  stock                                                                         
  comp…                                                                         
  Adju…             71,648           64,237            205,653          188,4…  
  net                5,984            6,067             24,285          24,374  
  inco…              7,013            2,850              7,561           2,850  
                     2,352            2,352              7,056           7,056  
  Dilu…    Three     3,151            (216)    Nine      6,904           3,294  
  Earn…    Months    1,726                -    Months    1,961               -  
  Per      Ended         -            2,665    Ended         -           2,665  
  Share    Septem…  (3,67…          (2,049)    Septe…  (8,296)          (6,51…  
  As       30,         521                -    30,       1,022           (513)  
  Repo…    2026     88,725    2025   75,906    2026    246,146    2025  221,7…  
 ────────────────────────────────────────────────────────────────────────────── 
  Net      $          5.45    $        4.46    $         15.43    $      12.89  
  inco…                                                                         
  Aver…                                                                         
  numb…                                                                         
  of                13,135           14,409             13,329          14,620  
  shar…                                                                         
  outs…                                                                         
                                                                                
  Adju…                                                                         
  Dilu…                                                                         
  Earn…                                                                         
  Per                                                                           
  Share                                                                         
  Adju…                                                                         
  net      $          6.75    $        5.27    $         18.47    $      15.16  
  inco…                                                                         
  Aver…                                                                         
  numb…                                                                         
  of                13,135           14,409             13,329          14,620  
  shar…                                                                         
  outs…                                                                         
                                                                                
  (1)                                                                           
  The                                                                           
  tax                                                                           
  impa…                                                                         
  of                                                                            
  pre-…                                                                         
  adju…                                                                         
  was                                                                           
  calc…                                                                         
  using                                                                         
  the                                                                           
  effe…                                                                         
  tax                                                                           
  rate                                                                          
  of                                                                            
  the                                                                           
  oper…                                                                         
  unit                                                                          
  for                                                                           
  which                                                                         
  each                                                                          
  adju…                                                                         
  is                                                                            
  asso…                                                                         
                                                                                
  The                                                                           
  "Foo…                                                                         
  to                                                                            
  Fina…                                                                         
  Stat…                                                                         
  are                                                                           
  inte…                                                                         
  parts                                                                         
  of                                                                            
  this                                                                          
  fina…                                                                         
  info…                                                                         
                                                                                
                                                                                
                                                                                
  CHEM…                                                                         
  CORP…                                                                         
  AND                                                                           
  SUBS…                                                                         
  COMP…                                                                         
  OPER…                                                                         
  STAT…                                                                         
  FOR                                                                           
  VITAS                                                                         
  SEGM…                                                                         
  (una…                                      For                                
                                             the                                
  OPER…  Three                               Nine                               
  STAT…  Mont…                               Months                             
  Net    Ended                               Ended                              
  reve…  Sept…                               Septe…                             
  ($00…  30,                                 30,                                
  (c)    2026              2025              2026              2025             
 ────────────────────────────────────────────────────────────────────────────── 
  Home…  $      405,9…     $     362,…       $       1,16…     $     1,072…     
  Inpa…         36,407           33,0…               108,…           100,1…     
  Cont…         21,159           19,9…               58,6…           68,222     
  care                                                                          
  Other          6,421           5,807               18,2…           16,898     
  Subt…  $      469,9…     $     421,…       $       1,35…     $     1,257…     
  Room                                                                          
  and           -3,982           -3,8…               -11,…           -11,2…     
  boar…                                                                         
  net                                                                           
  Cont…         -7,743           -3,5…               -17,…           -9,875     
  allo…                                                                         
  Medi…                                                                         
  cap             -828           -6,0…               -3,7…           -24,7…     
  allo…                                                                         
  Net    $      457,4…     $     407,…       $       1,32…     $     1,211…     
  Reve…                                                                         
  Net                                                                           
  reve…                                                                         
  as a                                                                          
  perc…                                                                         
  of                                                                            
  total                                                                         
  befo…                                                                         
  Medi…                                                                         
  cap                                                                           
  allo…                                                                         
  Home…           86.4  %         86.0  %             86.3  %          85.3  %  
  Inpa…            7.7             7.9                 8.0              8.0     
  Cont…            4.5             4.7                 4.3              5.4     
  care                                                                          
  Other            1.4             1.4                 1.4              1.3     
  Subt…          100.0           100.0               100.0            100.0     
  Room                                                                          
  and             -0.8            -0.8                -0.8             -0.9     
  boar…                                                                         
  net                                                                           
  Cont…           -1.7            -0.8                -1.3             -0.8     
  allo…                                                                         
  Medi…                                                                         
  cap             -0.2            -1.4                -0.3             -2.0     
  allo…                                                                         
  Net             97.3  %         97.0  %             97.6  %          96.3  %  
  Reve…                                                                         
  Days                                                                          
  of                                                                            
  care                                                                          
  Home…         1,872…           1,68…               5,35…           4,980…     
  Nurs…         312,6…           309,…               910,…           923,4…     
  home                                                                          
  Resp…         12,502           12,1…               35,6…           33,619     
  Subt…                                                                         
  rout…                                                                         
  home…         2,197…           2,00…               6,30…           5,937…     
  and                                                                           
  resp…                                                                         
  Inpa…         30,494           28,5…               90,6…           86,447     
  Cont…         19,683           18,3…               55,0…           62,576     
  care                                                                          
  Total         2,247…           2,05…               6,44…           6,086…     
                                                                                
  Numb…                                                                         
  of                                                                            
  days                                                                          
  in                92              92                 273              273     
  rele…                                                                         
  time                                                                          
  peri…                                                                         
  Aver…                                                                         
  daily                                                                         
  cens…                                                                         
  ("AD…                                                                         
  (day…                                                                         
  Home…         20,348           18,3…               19,6…           18,245     
  Nurs…          3,399           3,361               3,335            3,383     
  home                                                                          
  Resp…            136             132                 131              123     
  Subt…                                                                         
  rout…                                                                         
  home…         23,883           21,8…               23,0…           21,751     
  and                                                                           
  resp…                                                                         
  Inpa…            331             310                 332              317     
  Cont…            214             199                 202              229     
  care                                                                          
  Total         24,428           22,3…               23,6…           22,297     
                                                                                
  Total         18,995           17,7…               57,5…           53,398     
  Admi…                                                                         
  Total         18,426           17,3…               55,1…           52,931     
  Disc…                                                                         
  Aver…                                                                         
  leng…                                                                         
  of             103.5           109.7               102.5            121.9     
  stay                                                                          
  (day…                                                                         
  Medi…                                                                         
  leng…                                                                         
  of              17.0            18.0                16.0             18.0     
  stay                                                                          
  (day…                                                                         
                                                                                
  ADC                                                                           
  by                                                                            
  major                                                                         
  diag…                                                                         
  Cere…           44.1  %         44.1  %             44.4  %          44.6  %  
  Neur…           11.2            11.6                11.1             11.8     
  Canc…            9.2            10.1                 9.4              9.8     
  Card…           16.8            15.9                16.6             16.0     
  Resp…            8.1             7.7                 7.9              7.4     
  Other           10.6            10.6                10.6             10.4     
  Total          100.0  %        100.0  %            100.0  %         100.0  %  
  Admi…                                                                         
  by                                                                            
  major                                                                         
  diag…                                                                         
  Cere…           28.0  %         27.1  %             27.5  %          27.6  %  
  Neur…            6.7             6.9                 6.9              6.8     
  Canc…           24.7            26.6                24.3             25.9     
  Card…           14.9            14.3                15.3             14.7     
  Resp…           12.3            10.5                12.2             10.9     
  Other           13.4            14.6                13.8             14.1     
  Total          100.0  %        100.0  %            100.0  %         100.0  %  
                                                                                
  Esti…                                                                         
  unco…                                                                         
  acco…                                                                         
  as a             1.2  %          0.9  %              1.3  %           0.8  %  
  perc…                                                                         
  of                                                                            
  reve…                                                                         
                                                                                
  Acco…                                                                         
  rece…                                                                         
  --                                                                            
  Days                                                                          
  of                                                                            
  reve…                                                                         
  outs…           39.0            37.5                n.a.             n.a.     
  unap…                                                                         
  Medi…                                                                         
  paym…                                                                         
  Days                                                                          
  of                                                                            
  reve…                                                                         
  outs…           37.4            34.0                n.a.             n.a.     
  unap…                                                                         
  Medi…                                                                         
  paym…                                                                         
                                                                                
                                                                                
                                                                                
  CHE…                                                                          
  COR…                                                                          
  AND                                                                           
  SUB…                                                                          
  COM…                                                                          
  FOO…  Incl…                                                                   
  TO    in                                                                      
  FIN…  the                                                                     
  STA…  resu…                                                                   
  FOR   of                                                                      
  THE   oper…                                                                   
  THR…  for                                                                     
  AND   2026                                                                    
  NINE  are                                                                     
  MON…  the                                                                     
  END…  foll…                                                                   
  SEP…  sign…                                                                   
  30,   cred…                                                                   
  2026  which                                                                   
  AND   may                                                                     
  2025  not                                                                     
  (un…  be       Three                                                          
        indi…    Mont…                                                          
  (a)   of       Ended                                                          
        ongo…    Sept…                                                          
        oper…    30,                                                            
        (in      2026                                                           
        thou…    VITAS           Roto…           Corp…           Conso…         
 ────────────────────────────────────────────────────────────────────────────── 
        Legal    $      -6,7…    $          -    $       -308    $       -7,0…  
        sett…                                                                   
        Stock                                                                   
        opti…               -               -           -5,9…            -5,9…  
        expe…                                                                   
        Long…                                                                   
        ince…               -               -           -3,1…            -3,1…  
        comp…                                                                   
        Amor…                                                                   
        of                                                                      
        reac…               -           -2,3…               -            -2,3…  
        fran…                                                                   
        agre…                                                                   
        Acqu…               -           -1,7…               -            -1,7…  
        expe…                                                                   
        Pret…                                                                   
        impa…           -6,7…           -4,0…           -9,4…            -20,…  
        on                                                                      
        earn…                                                                   
        Exce…                                                                   
        tax                                                                     
        expe…               -               -            -521             -521  
        on                                                                      
        stock                                                                   
        comp…                                                                   
        Inco…                                                                   
        tax                                                                     
        bene…           1,629             950           1,091            3,670  
        on                                                                      
        the                                                                     
        above                                                                   
        Afte…                                                                   
        impa…    $      -5,0…    $      -3,1…    $      -8,8…    $       -17,…  
        on                                                                      
        earn…                                                                   
                                                                                
                 Nine                                                           
                 Mont…                                                          
                 Ended                                                          
                 Sept…                                                          
                 30,                                                            
                 2026                                                           
                 VITAS           Roto…           Corp…           Conso…         
                                                                                
        Stock                                                                   
        opti…    $          -    $          -    $      -24,…    $       -24,…  
        expe…                                                                   
        Legal           -7,2…               -            -308            -7,5…  
        sett…                                                                   
        Amor…                                                                   
        of                                                                      
        reac…               -           -7,0…               -            -7,0…  
        fran…                                                                   
        agre…                                                                   
        Long…                                                                   
        ince…               -               -           -6,9…            -6,9…  
        comp…                                                                   
        Acqu…              -8           -1,9…               -            -1,9…  
        expe…                                                                   
        Pret…                                                                   
        impa…           -7,2…           -9,0…           -31,…            -47,…  
        on                                                                      
        earn…                                                                   
        Exce…                                                                   
        tax                                                                     
        expe…               -               -           -1,0…            -1,0…  
        on                                                                      
        stock                                                                   
        comp…                                                                   
        Inco…                                                                   
        tax                                                                     
        bene…           1,764           2,100           4,432            8,296  
        on                                                                      
        the                                                                     
        above                                                                   
        Afte…                                                                   
        impa…    $      -5,4…    $      -6,9…    $      -28,…    $       -40,…  
        on                                                                      
        earn…                                                                   
                                                                                
        Incl…                                                                   
        in                                                                      
        the                                                                     
        resu…                                                                   
        of                                                                      
        oper…                                                                   
        for                                                                     
        2025                                                                    
        are                                                                     
        the                                                                     
  (b)   foll…                                                                   
        sign…                                                                   
        cred…                                                                   
        which                                                                   
        may                                                                     
        not                                                                     
        be                                                                      
        indi…                                                                   
        of                                                                      
        ongo…                                                                   
        oper…                                                                   
        (in                                                                     
        thou…                                                                   
                 Three                                                          
                 Mont…                                                          
                 Ended                                                          
                 Sept…                                                          
                 30,                                                            
                 2025                                                           
                 VITAS           Roto…           Corp…           Conso…         
                                                                                
        Stock                                                                   
        opti…    $          -    $          -    $      -6,0…    $       -6,0…  
        expe…                                                                   
        Legal           -2,8…               -               -            -2,8…  
        sett…                                                                   
        Amor…                                                                   
        of                                                                      
        reac…               -           -2,3…               -            -2,3…  
        fran…                                                                   
        agre…                                                                   
        Long…                                                                   
        ince…               -               -             216              216  
        comp…                                                                   
        Other               -               -           -2,6…            -2,6…  
        Pret…                                                                   
        impa…           -2,8…           -2,3…           -8,5…            -13,…  
        on                                                                      
        earn…                                                                   
        Inco…                                                                   
        tax                                                                     
        bene…             698             546             805            2,049  
        on                                                                      
        the                                                                     
        above                                                                   
        Afte…                                                                   
        impa…    $      -2,1…    $      -1,8…    $      -7,7…    $       -11,…  
        on                                                                      
        earn…                                                                   
                                                                                
                 Nine                                                           
                 Mont…                                                          
                 Ended                                                          
                 Sept…                                                          
                 30,                                                            
                 2025                                                           
                 VITAS           Roto…           Corp…           Conso…         
                                                                                
        Stock                                                                   
        opti…    $          -    $          -    $      -24,…    $       -24,…  
        expe…                                                                   
        Amor…                                                                   
        of                                                                      
        reac…               -           -7,0…               -            -7,0…  
        fran…                                                                   
        agre…                                                                   
        Long…                                                                   
        ince…               -               -           -3,2…            -3,2…  
        comp…                                                                   
        Legal           -2,8…               -               -            -2,8…  
        sett…                                                                   
        Other               -               -           -2,6…            -2,6…  
        Pret…                                                                   
        impa…           -2,8…           -7,0…           -30,…            -40,…  
        on                                                                      
        earn…                                                                   
        Exce…                                                                   
        tax                                                                     
        bene…               -               -             513              513  
        on                                                                      
        stock                                                                   
        comp…                                                                   
        Inco…                                                                   
        tax                                                                     
        bene…             698           1,637           4,177            6,512  
        on                                                                      
        the                                                                     
        above                                                                   
        Afte…                                                                   
        impa…    $      -2,1…    $      -5,4…    $      -25,…    $       -33,…  
        on                                                                      
        earn…                                                                   
                                                                                
                                                                                
                                                                                
                                                                                
       VITAS has 14 large (greater than 450 ADC), 25 medium (greater than 200   
       but less than 450 ADC) and 21 small (less than 200 ADC) hospice          
  (c)  programs.  Of Vitas' 33 Medicare provider numbers, for the current cap   
       year, 21 provider numbers have a Medicare cap cushion of greater than    
       10%, seven provider numbers have a Medicare cap cushion between 0% and   
       10%, and five provider numbers have a Medicare cap liability.            
                                                                                

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CHE/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.